Summary of all included studies in the meta-analysis and the characteristics of their patients
| Included studies and baseline characteristics of their patients | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Author (year) | Medication | Number of cases | Disease duration (years) | Study duration (weeks) | BASFI | BASDAI | ||||
| Treatment | Control | Treatment | Control | Treatment (SD) | Control (SD) | Treatment (SD) | Control (SD) | |||
| Patients with ankylosing spondylitis | ||||||||||
| van der Heijde (2006)15 | ADA | 208 | 107 | 11.3 | 10 | 12 | 5.2 (2.2) | 5.6 (2.2) | 6.3 (1.7) | 6.3 (1.7) |
| Lambert (2007)16 | ADA | 38 | 44 | 14.5 | 12.1 | 12 | 5.3 (2) | 5.6 (2.2) | 6.2 (1.7) | 6.5 (1.6) |
| Hu (2012)17 | ADA | 26 | 20 | 7.4 | 7.6 | 12 | 3.7 (2.1) | 3.9 (2) | 5.9 (1.4) | 6.2 (1.1) |
| Huang (2013)18 | ADA | 229 | 115 | 8.1 | 7.7 | 12 | 4.3 (2.3) | 4.4 (2.3) | 6.0 (1.4) | 6.2 (1.4) |
| Landewé (2014)19 | CZP 200 mg | 65 | 57 | 8.8 | 10.2 | 12 | 5.6 (2.3) | 6.0 (2) | 6.5 (1.7) | 6.4 (1.9) |
| Landewé (2014)19 | CZP 400 mg | 56 | 57 | 8.8 | 10.2 | 12 | 5.7 (2.3) | 6.0 (2) | 6.2 (1.3) | 6.4 (1.9) |
| Gorman (2002)20 | ETA | 20 | 20 | 15 | 12 | 24 | 4.5 (2.1) | 3.2 (2.5) | – | – |
| Davis (2003)21 | ETA | 138 | 139 | 10.1 | 10.5 | 24 | 5.2 (1.8) | 5.6 (1.7) | 5.8 (1.5) | 6 (1.4) |
| Calin (2004)22 | ETA | 45 | 39 | 15 | 9.7 | 12 | 6.0 (–) | 5.7 (–) | 6.1 (–) | 5.9 (–) |
| van der Heijde (2006)23 | ETA 25 mg twice weekly | 150 | 51 | 10 | 8 | 12 | 5.8 (2) | 6.0 (1.9) | 5.9 (1.7) | 6.1 (1.4) |
| van der Heijde (2006)23 | ETA 50 mg once weekly | 155 | 51 | 9 | 8 | 12 | 6.1 (2) | 6.0 (1.9) | 6.2 (1.7) | 6.1 (1.4) |
| Barkham (2010)24 | ETA | 15 | 17 | 11 | 20 | 12 | 5.6 (2) | 5.3 (1.8) | 6.1 (1.7) | 5.5 (1.7) |
| Dougados (2011)25 | ETA | 39 | 43 | 19 | 23 | 12 | 6.3 (2) | 5.7 (1.9) | 6.4 (1.2) | 5.8 (1.5) |
| Inman (2008)26 | GLM | 138 | 78 | 9.5 | 16 | 14 | 5.0 (2.6) | 4.9 (2.4) | 6.6 (1.5) | 6.6 (1.5) |
| Braun (2002)27 | INF | 34 | 35 | 16.4 | 14.9 | 12 | 5.4 (1.8) | 5.1 (2.2) | 6.5 (1.2) | 6.3 (1.4) |
| van den Bosch (2002)28 | INF | 9 | 12 | 10 | 17 | 12 | 4.7 (–) | 5.9 (–) | 5.9 (–) | 5.3 (–) |
| Marzo-Ortega (2005)29 | INF | 28 | 14 | 8 | 10 | 30 | 6.7 (–) | 6.0 (–) | 6.9 (–) | 6.4 (–) |
| van der Heijde (2005)30 | INF | 201 | 78 | 7.7 | 13.2 | 24 | 5.7 (–) | 6.0 (–) | 6.6 (–) | 6.5 (–) |
| Patients with non-radiographic axial spondyloarthritis | ||||||||||
| Haibel (2008)31 | ADA | 22 | 24 | 7 | 8 | 12 | 5.4 (2) | 4.9 (1.6) | 6.5 (1.2) | 6.2 (1.3) |
| Sieper (2013)4 | ADA | 91 | 94 | 10.1 | 10.1 | 12 | 4.5 (1.9) | 4.9 (2.3) | 6.4 (1.5) | 6.5 (1.6) |
| Landewé (2014)19 | CZP 200 mg | 46 | 50 | 4.8 | 4.5 | 12 | 4.8 (2.2) | 4.9 (2.2) | 6.5 (1.4) | 6.4 (1.5) |
| Landewé (2014)19 | CZP 400 mg | 51 | 50 | 7.3 | 4.5 | 12 | 5.1 (2.4) | 4.9 (2.2) | 6.6 (1.6) | 6.4 (1.5) |
| Dougados (2013)32 | ETA | 106 | 109 | 2.4 | 2.5 | 12 | 4.2 (2.5) | 3.9 (2.5) | 6.0 (1.8) | 6.0 (1.9) |
| Barkham (2009)33 | INF | 20 | 20 | 1.4 | 1.1 | 16 | 4.4 (–) | 4.1 (–) | 5.9 (–) | 5.8 (–) |
ADA, adalimumab; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CZP, certolizumab; ETA, etanercept; GLM, golimumab; INF, infliximab.